by Portfolio Grader | December 13, 2013 8:30 am
This week, the overall grades of three pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
VIVUS, Inc.’s (VVUS) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. As of Dec. 13, 2013, 30.9% of outstanding VIVUS, Inc. shares were held short. To get an in-depth look at VVUS, get Portfolio Grader’s complete analysis of VVUS stock.
Cempra, Inc.’s (CEMP) rating weakens this week, dropping to a D versus last week’s C. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics Incorporated. (CORT) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For a full analysis of CORT stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: https://investorplace.com/2013/12/3-pharmaceutical-stocks-to-sell-now-vvus-cemp-cort-34/
Short URL: http://invstplc.com/1nv5izo
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.